Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SD-169 (SD 169) 是一种可口服的 ATP 竞争性MAPK p38α抑制剂,IC50值为 3.2 nM。它对p38β MAPK 的IC50值为 122 nM。它通过抑制 T 细胞的浸润和活化阻止糖尿病的发展。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 178 | 现货 | ||
25 mg | ¥ 293 | 现货 | ||
50 mg | ¥ 455 | 现货 | ||
100 mg | ¥ 690 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 120 | 现货 |
产品描述 | SD-169 (SD 169) is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor. |
靶点活性 | p38α MAPK:3.2 nM (IC50), p38β MAPK:122 nM (IC50) |
体内活性 | Animals were gavaged with Scios SD-169 (10 or 30 mg/kg) or excipient (PEG300) 1 day before and daily after crush injury to the sciatic nerve.?SD-169 is a proprietary oral inhibitor of p38 MAPK activity.?The rate of axonal regeneration was determined by the functional pinch test and was significantly increased in treated animals 8 days after crush injury (P < 0.05;?30 mg/kg dose).?In SD-169-treated animals with nerve transection, nerve fibers regenerating through a silicone chamber were morphologically more mature than untreated nerves when observed 28 days after transection.?TNF immunofluorescence of distal nerve segments after crush injury suggested that SD-169 reduced SC TNF protein[1]. |
别名 | SD 169, 1H-吲哚-5-甲酰胺 |
分子量 | 160.17 |
分子式 | C9H8N2O |
CAS No. | 1670-87-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (62.43 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 6.2434 mL | 31.2168 mL | 62.4337 mL | 156.0842 mL |
5 mM | 1.2487 mL | 6.2434 mL | 12.4867 mL | 31.2168 mL | |
10 mM | 0.6243 mL | 3.1217 mL | 6.2434 mL | 15.6084 mL | |
20 mM | 0.3122 mL | 1.5608 mL | 3.1217 mL | 7.8042 mL | |
50 mM | 0.1249 mL | 0.6243 mL | 1.2487 mL | 3.1217 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SD-169 1670-87-7 MAPK p38 MAPK HSPs p38α kinases SD169 SD 169 protein inhibit Inhibitor heat diabete mitogen-activated proteins 1H-吲哚-5-甲酰胺 shock inhibitor